Investigacion

Jose Luis García Giménez

Jose Luis García Giménez
Jose Luis García Giménez
j.luis.garcia@uv.es

Jose Luis García Giménez

Bachelor in Chemical Science in 2002 and Bachelor in Biochemistry in 2004 (University of Valencia). PhD. Degree in Chemistry in 2007 (University of Valencia). Post-Doctoral fellow in Hake’s lab in Adolf Butenandt Institute, LMU University, Munich (Germany), one of the most important epigenetic laboratories in Europe. CIBER’s PhD Researcher in epigenetics and oxidative stress in Rare Diseases. 

Over 12 years of continuous research in 20 funded projects (as IP and collaborator). More than 46 publications in the field of rare diseases, epigenetics, biomarkers, and oxidative stress. Current research collaborations with clinicians and industry. 3 International Patents: 1 Patent in methods for detecting oxidized histones (ES2396387(B1) 1 European patent on miRNAs as biomarkers for AIS diagnosis/prognosis (PCT/EP2016/063935) and 1 European patent on circulating histones as biomarker for sepsis (PCT/EP2017/078362). Member of the International Rare Diseases Research Consortium (IRDiRC). Translational Research Experimental Medicine, and Therapeutics on Charcot-Marie-Tooth Disease (TREAT-CMT). Editor of Translational Epigenetic Series Volume “Epigenetic Biomarkers and Diagnostics” Academic Press Elsevier in 2015. 6 National and international awards. 

Founder and CEO of EpiDisease S.L., the former Spin-Off from the Center for Biomedical Network Research (CIBER-ISCIII). EpiDisease has been received NEOTEC funds from CDTI and received the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020.